CERUBIDINE (daunorubicin hydrochloride) by Thayer Medical is clinical pharmacology mechanism of action daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. First approved in 1979.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
CERUBIDINE (daunorubicin hydrochloride) is a cytotoxic anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, causing single and double-strand DNA breaks. It is indicated for acute leukemias and lymphomas across pediatric and adult populations. The drug demonstrates broad antitumor activity through multiple mechanisms including DNA intercalation, topoisomerase inhibition, polymerase interference, and free radical generation.
As loss of exclusivity approaches, the brand team will shift focus from growth initiatives to cost management, generic defense strategies, and organizational consolidation.
CLINICAL PHARMACOLOGY Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II…
Worked on CERUBIDINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CERUBIDINE in its LOE phase offers limited growth opportunity but provides valuable experience in legacy product management, generic transition strategy, and mature market operations. This role suits professionals seeking to learn cost-containment, payer negotiation, and organizational change management in a declining-revenue environment.